How much funding has ResistanceBio raised?

ResistanceBio has raised $12.8M in total funding, most recently a Seed round.

Who are ResistanceBio's investors?

ResistanceBio's investors include Alumni Ventures, Cherubic Ventures, NFX, Y Combinator Continuity Fund.

When was ResistanceBio founded?

ResistanceBio was founded in 2016.

Where is ResistanceBio headquartered?

ResistanceBio is headquartered in Menlo Park.

What industry is ResistanceBio in?

ResistanceBio operates in Drug Discovery, Healthcare.

How many employees does ResistanceBio have?

ResistanceBio has 11-50 employees.

ResistanceBio

Closed

Menlo Park · Founded 2016 · $12.8M raised

Drug Discovery

Healthcare

YC W19

Headquarters: Menlo Park
Employees: 11–50
Founded: 2016
Website: resistance.bio

Total Funding: $12.8M
Last Round: $12.8M SeedJan 2024
Rounds: 1

About

ResistanceBio built ResCu, a cell culture system that mimics the size and diversity of human tumors to model how cancer responds to treatment before drug resistance develops. The platform helps pharmaceutical and biotech partners discover and overcome clinical treatment resistance pre-clinically, targeting a mechanism responsible for roughly 90% of cancer mortality. Co-founded by Nicholas Goldner and Chris Bulow, the company emerged from Y Combinator's Winter 2019 batch and is headquartered in Menlo Park, California.

Summary

ResistanceBio is a Drug Discovery company based in Menlo Park, founded in 2016. It has raised $12.8M in total across 1 round, most recently a $12.8M Seed round in Jan 2024. Investors include Alumni Ventures, Cherubic Ventures and NFX.